# PT-141 Dosage: The Approved Label and the Research Context

> PT-141 dosage in the research record: the approved 1.75 mg subcutaneous label dose for HSDD, half-life, pharmacokinetics, and the doses studied. No personal dosing advice.

The approved label dose, the doses studied across development, and the pharmacokinetics — reported as documented, never as a recommendation.

## Before the numbers

This page reports PT-141 dosage as it appears in the approved label and the published studies — not as advice for any person. The only dose with regulatory standing is the approved one: for HSDD in premenopausal women, the US prescribing information specifies 1.75 mg injected under the skin, as needed, at least 45 minutes before anticipated sexual activity, with no more than one dose per 24 hours and no more than eight doses per month [7]. The compound clears the body fairly quickly — its terminal half-life (the time for the blood level to fall by half late in the curve) is about 2.7 hours [7]. Across development, researchers studied other doses and routes, which are described below for context only. No number here is a suggestion to use, and material sold as an unregulated "research chemical" carries no verified concentration at all, which makes any informal dosing inherently uncertain.

## PT-141 dosage: the approved label

The authoritative PT-141 dosage is the FDA-approved bremelanotide label: 1.75 mg subcutaneous, as needed, at least 45 minutes before anticipated sexual activity, capped at one dose per 24 hours and eight doses per month [7]. That cap matters — it is a safety limit, not an arbitrary ceiling. The label restricts use to acquired, generalized HSDD in premenopausal women and carries a warning on transient blood-pressure increase, contraindicating use in uncontrolled hypertension or known cardiovascular disease [7]. These are documented label facts, reported here verbatim from the source, not personal instructions.

## PT-141 dosage for women versus other studied doses

Beyond the approved PT-141 dosage for women (1.75 mg as needed), development studied a range. Phase 2 subcutaneous dose-finding in women tested 0.75, 1.25, and 1.75 mg [3]. Early intranasal research in men with erectile dysfunction escalated to roughly 7-20 mg, with a statistically significant erectile response appearing above 7 mg [1]. A Phase 1 obesity research protocol in women used subcutaneous doses up to 2.5 mg, up to three times daily for 15 days — strictly a research protocol, never an approved regimen [1]. The contrast is instructive: the approved as-needed dose is far lower and far less frequent than the metabolic research doses, and only the 1.75 mg as-needed subcutaneous schedule carries an approval [7].

## How long does PT-141 last: half-life and pharmacokinetics

How long PT-141 lasts in the body is set by its pharmacokinetics. After subcutaneous injection, the median time to peak blood level (Tmax) is roughly 0.5 to 1.0 hour, and the terminal half-life is approximately 2.7 hours (range 1.9-4.0 hours) per the US label; early intranasal studies reported a similar 1.85-2.09 hours [7]. The volume of distribution is about 25.0 L and clearance about 6.5 L/hr, with roughly 21% serum protein binding; the compound is broken down by hydrolysis of its cyclic-peptide bonds and by peptidase digestion, and a radiolabeled dose was excreted 64.8% renally and 22.8% fecally [7]. A practical reading: blood levels rise within the first hour and fall substantially within several hours — the molecule is not long-lived in circulation. The full source is on the [PT-141 references](/references) page.

---

A blue-phosphor terminal reading of the PT-141 (bremelanotide) record — the one approved use logged first, the label dose and trial figures read back verbatim, the off-label and research-chemical lines flagged amber, and the unverified field reports fenced off as such; no clinic behind the prompt and nothing here dosed, sourced, prescribed, or sold.